Trials / Unknown
UnknownNCT05550142
A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China
A Preliminary Exploratory Cohort Study to Evaluate Safety, Tolerability and Immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in Participants Aged 18 Years and Over in China
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- AIM Vaccine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a preliminary exploratory cohort study to evaluate safety, tolerability and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose | 50μg/dose |
| BIOLOGICAL | SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose | 100μg/dose |
| DRUG | Placebo | Saline solution |
Timeline
- Start date
- 2022-09-16
- Primary completion
- 2022-12-19
- Completion
- 2024-03-01
- First posted
- 2022-09-22
- Last updated
- 2023-02-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05550142. Inclusion in this directory is not an endorsement.